MedTrace Logo

The Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal-Vascular Fraction of Adipose Tissue Cells for Treatment of Knee Joint Arthrosis

NCT04050111 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-08-08

No results posted yet for this study

Summary

Stromal vascular fraction of cells (SVF) will be extracted from lipoaspirate by enzymatic digestion. SVF will be administered in a single dose intraarticularly. All patients will receive cell therapy.This is a single arm study with no control.

Conditions

Interventions

BIOLOGICAL

Stromal-vascular fraction

Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue

Sponsors & Collaborators

  • Swiss Medica XXI Century S.A.

    lead INDUSTRY

Principal Investigators

  • Sergey L Mikheev, MD, PhD · Head of Swiss Medica XXI Century S.A.

  • Ilya I Eremin, MD, PhD · Chief scientific officer of Swiss Medica XXI Century S.A.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-21
Primary Completion
2021-02-22
Completion
2021-08-22

Countries

  • Russia
  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04050111 on ClinicalTrials.gov